drugset

drugset / Trial / NCT05149378

Venetoclax Based Regimen for R/R T-ALL

NCT05149378 ↗

Phase 2 Completed 25 enrolled The First Affiliated Hospital of Soochow University Affiliated Hospital of Nantong University · collab Canglang Hospital of Suzhou · collab Jining Medical University · collab Nanyang Central Hospital of Henan Province · collab Southern Medical University, China · collab Suzhou Hospital of Traditional Chinese Medicine · collab The First Affiliated Hospital of Anhui Medical University · collab The First Affiliated Hospital of Bengbu Medical University · collab The Second People's Hospital of Huai'an · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.

Timeline

Start: 2021-11-01
Primary completion: 2024-12-31
Completion: 2024-12-31

Publications

Cao HY, Zhang H, Zhang Y, Hu XH, Yang L, Yang YL, Zhang YM, Wu B, Huang ZQ, Huang R, Wang RJ, Wan CL, Wu DP, Dai HP, Xue SL. Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025 Dec;12(12):e946-e955. doi: 10.1016/S2352-3026(25)00284-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	75 mg/m2	Subcutaneous
Subject	Venetoclax	Small molecule	400 mg	Oral

Indications